Clinical trial
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants…
NCT00437268 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00437268 |
|---|---|
| Title | A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer |
| Official title | A Randomized Phase 2 Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Recurrent Colorectal Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumor |
| Intervention type | Drug |
| Interventions | enzastaurin, irinotecan, cetuximab |
| Enrollment | 26 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Feb 19, 2007 |
| Last update posted | Jul 21, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: